Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'

Abstract

We respond to concerns expressed by Pacifici and Shore (2019) about a recent paper (Lees-Shepard and Goldhamer, 2018a) in which we reported that the drug palovarotene can have severe side effects in a mouse model of fibrodysplasia ossificans progressiva.

Keywords

• Fibrodysplasia ossificans progressiva
• Palovarotene
• RARγ agonist
• heterotopic ossification
• skeletal toxicity
• growth plate